Categories
News

Drug firms giving MPs ‘hidden’ funding, research shows – The Guardian

Drug companies are giving groups of MPs and peers that campaign on health issues hundreds of thousands of pounds a year in “hidden” funding that could hand them “undue influence”, research has found.

The pharmaceutical industry has built up a “hidden web of policy influence” over dozens of all-party parliamentary groups (APPGs) at Westminster by making hundreds of “non-transparent” payments to them, as part of the industry’s wider effort to lobby those in power, researchers claim.

…[R]esearch found:
16 health-related APPGs received 168 payments from 35 drug firms worth £1.2m in 2012-18 – one-sixth of their total funding

Two APPGs, on health and cancer, accepted more than £600,000 in that time

50 health-focused APPGs received almost another £1m in 304 payments from patient organisations or health charities, which themselves take sums of money from big pharma

https://www.theguardian.com/business/2021/jun/25/drug-firms-giving-mps-hidden-funding-research-shows

Categories
Publications

Manipulative magnetic nanomedicine: the future of COVID-19 pandemic/endemic therapy – Taylor & Francis Online

Published 14 Dec 2020

Nanobiotechnology is emerging very promising to investigate novel methodologies for managing COVID-19 pandemic/endemic successfully. In this direction, experts have explored the opto-electro-magnetic nanosystem to detect the SARS-CoV-2 virus using a biosensing approach. Such optical, electrical, or magnetic biosensors function based on geno-sensing and immune-sensing has detected the SARS-CoV-2 virus selectively at a very low level. These efficient-miniaturized biosensors can be operated using a smartphone and promoted for clinical application for early-stage diagnostics of COVID-19 infection. The successful integration of these SARS-CoV-2 virus sensors with AI and IoMT enables virus detection at point-of-location and sharing of bioinformatics with the medical center at the same time for timely therapeutics decision. This approach is also useful for tracking tasks and managing COVID-19 infection according to patient infection profiling. To avoid human-to-human SARS-CoV-2 virus transmission, experts have developed stimuli-responsive nanotechnology enable which can not only trap aerosol of virus size but can eradicate viruses on applying external stimulation for example nanoenable photo-sensitive virus degradation. Various types of clothes containing nanoparticles have demonstrated SARS-CoV-2 virus trapping and eradication successfully [2,9]. However, significant attention is required to increase the production and distribution of these masks for public use.

https://www.tandfonline.com/doi/full/10.1080/17425247.2021.1860938

Categories
Opinion

Release Us From This Servitude – James Delingpole & Toby Young, London Calling

Fresh from their smash reunion tour this weekend, James and Toby recap the weekend’s anti-lockdown march that wound from Parliament Square to Toby’s doorstep.

We then parse the testimony of the PM’s former “top man,” Dominic Cummings, before the House’s Health and Science select committees last week and who came out of it better. Do you want a Prime Minister or a Monarch (and by “monarch” we’re not talking about the one we’ve already got.)

https://ricochet.com/podcast/london-calling/release-us-from-this-servitude/

Categories
Alternative Media Videos

Dr. Hodkinson Interview – COVID-19 Vaccines, Infertility & Spike Protein Dangers

Dr. Hodkinson, here to discuss the dangers of the COVID-19 vaccines, the possibility of infertility, and the very real concerns about the vaccine-induced spike proteins and what new scientific research is clearly suggesting about their risks to your health.

Categories
Opinion

COVID-19 educational materials in schools use inappropriate emotional pressure – HART

Resources use inappropriate emotional pressure

The Human Medicines Regulations 2012 (the ‘Regulations’) apply to anything ‘designed to promote the … supply … or use of that [medicinal] product’, which according to the regulations amounts to an advertisement. As the materials do not properly encourage critical thinking and present information as fact without substantiation, it is entirely possible that the teaching materials and lessons delivering those materials amount to an advertisement and may constitute an offence.

However well meaning these materials might be, it appears that they have at least the potential to put emotional pressure on children and — potentially — coercively control children’s decisions in relation to the vaccine.  The materials are therefore incompatible with the NC and the government’s advice on Teachers’ Prevent Duty, which are there to help protect children.

Categories
News

More pandemic profiteers: COVID-19 vaccines have minted at least NINE new pharma billionaires – and their combined wealth is enough to buy shots for 780 MILLION people in low-income nations – Daily Mail

Nine executives from Moderna, BioNTech, ROVI and CanSino Biologics have all become billionaires throughout the pandemic 

Together they are now worth $19.3 billion – a combined net wealth greater than what it would cost to vaccinate the world’s poorest nations 

The list was compiled by the People’s Vaccine Alliance, a campaign group that includes Oxfam, UNAIDS, Global Justice Now and Amnesty International 

Moderna CEO Stéphane Bancel is now worth a whopping $4.3 billion after his company was granted emergency use authorization in the US in December

CEO and co-founder of BioNTech Ugur Sahin is close behind with a wealth of $4 billion, following its collaboration on a vaccine with Pfizer

Senior executives from CanSino Biologics have also become billionaires after it developed a one-shot vaccine that was approved for use in China this February  

It comes as world leaders will discuss at the G20 Global Health Summit whether to waive patent protections for COVID-19 vaccines

Supporters say it will allow more manufacturers to produce life-saving vaccines and increase their supply to poorer countries

https://www.dailymail.co.uk/news/article-9606183/COVID-19-vaccines-minted-NINE-new-pharma-billionaires.html

Categories
Publications

Risk in Vaccine Research and Development Quantified – PLOS ONE

Published in 20th March 2013

A database was actively compiled to include all vaccine projects in development from 1998 to 2009 in the pre-clinical development phase, clinical trials phase I, II and III up to Market Registration. The average vaccine, taken from the preclinical phase, requires a development timeline of 10.71 years and has a market entry probability of 6%. Stratification by disease area reveals pandemic influenza vaccine targets as lucrative.

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0057755

Categories
Publications

The four phases of clinical trials – Pfizer

The process of learning about and developing an investigational medicine is divided into four phases. At first, very few people receive the medicine being studied. The number of people participating in clinical studies grows along with our understanding of the investigational medicine, and the research continues as long as the potential benefits outweigh the risks.

https://www.pfizer.com/science/clinical-trials/guide-to-clinical-trials/phases

Categories
Publications

Graphene – All You Need to Know – nanowerk

The use of graphene-based materials in pharmaceutical nanotechnology has recently received more attention due to their unique chemical structure and physicochemical properties—including an ultra-high surface area, optical, thermal and electrical conductivities, and a good biocompatibility.

GO nanosheets tend to be hydrophilic and the surface contains reactive groups for an increased functionality or for loading drugs through covalent and non-covalent interactions. In addition, graphene-based nanomaterials can also be functionalized with diagnostic probes that have fluorescent and/or luminescent properties and can target ligands such as proteins, peptides, nucleic acids, antibodies, lipids, carbohydrates and folic acid.

In pharmaceutical applications, graphene-based nanomaterials possess a lot of potential for improving drug circulation times, in target drug and gene delivery systems, for acting as therapeutic agents and diagnostic tools, as well as graphene nanotheranostic agents that combine both diagnostic and therapy approaches in a single system.

The use of graphene-based materials in pharmaceutical nanotechnology has recently received more attention due to their unique chemical structure and physicochemical properties—including an ultra-high surface area, optical, thermal and electrical conductivities, and a good biocompatibility.

GO nanosheets tend to be hydrophilic and the surface contains reactive groups for an increased functionality or for loading drugs through covalent and non-covalent interactions. In addition, graphene-based nanomaterials can also be functionalized with diagnostic probes that have fluorescent and/or luminescent properties and can target ligands such as proteins, peptides, nucleic acids, antibodies, lipids, carbohydrates and folic acid.

In pharmaceutical applications, graphene-based nanomaterials possess a lot of potential for improving drug circulation times, in target drug and gene delivery systems, for acting as therapeutic agents and diagnostic tools, as well as graphene nanotheranostic agents that combine both diagnostic and therapy approaches in a single system.

The use of graphene-based materials in pharmaceutical nanotechnology has recently received more attention due to their unique chemical structure and physicochemical properties—including an ultra-high surface area, optical, thermal and electrical conductivities, and a good biocompatibility.

GO nanosheets tend to be hydrophilic and the surface contains reactive groups for an increased functionality or for loading drugs through covalent and non-covalent interactions. In addition, graphene-based nanomaterials can also be functionalized with diagnostic probes that have fluorescent and/or luminescent properties and can target ligands such as proteins, peptides, nucleic acids, antibodies, lipids, carbohydrates and folic acid.

In pharmaceutical applications, graphene-based nanomaterials possess a lot of potential for improving drug circulation times, in target drug and gene delivery systems, for acting as therapeutic agents and diagnostic tools, as well as graphene nanotheranostic agents that combine both diagnostic and therapy approaches in a single system.

The use of graphene-based materials in pharmaceutical nanotechnology has recently received more attention due to their unique chemical structure and physicochemical properties—including an ultra-high surface area, optical, thermal and electrical conductivities, and a good biocompatibility.

GO nanosheets tend to be hydrophilic and the surface contains reactive groups for an increased functionality or for loading drugs through covalent and non-covalent interactions. In addition, graphene-based nanomaterials can also be functionalized with diagnostic probes that have fluorescent and/or luminescent properties and can target ligands such as proteins, peptides, nucleic acids, antibodies, lipids, carbohydrates and folic acid.

In pharmaceutical applications, graphene-based nanomaterials possess a lot of potential for improving drug circulation times, in target drug and gene delivery systems, for acting as therapeutic agents and diagnostic tools, as well as graphene nanotheranostic agents that combine both diagnostic and therapy approaches in a single system.

An international team of researchers has developed a drug delivery technique that utilizes graphene strips as “flying carpets” to deliver two anticancer drugs sequentially to cancer cells, with each drug targeting the distinct part of the cell where it will be most effective. The technique was found to perform better than either drug in isolation when tested in a mouse model targeting a human lung cancer tumor.

https://web.archive.org/web/20220403192812/https://www.nanowerk.com/what_is_graphene.php

Categories
News

With IFFIm, donors have an immediate impact – IFFIm

IFFIm’s financial base consists of grants from 10 sovereign sponsors. By signing the grant agreements, countries agree to pay these obligations in a specified schedule of payments.

CountryUS$ equivalentCurrency of pledge
United KingdomUS$ 3,652 million over 23 yearsGBP 2,130 million
France FranceUS$ 1,884 million over 20 yearsEUR 1,390 million
ItalyUS$ 821 million over 25 yearsEUR 654 million* *Includes a pledge to support the Coalition for Epidemic Preparedness Innovations (CEPI) through Gavi for the development of COVID-19 vaccine candidates.  
Norway NorwayUS$ 647 million over 25 yearsUS$ 27 million & NOK 5,100 million* *Includes additional pledges to support the Coalition for Epidemic Preparedness Innovations (CEPI) through Gavi for the development of COVID-19 vaccine candidates
The Netherlands The NetherlandsUS$ 487 million over 20 yearsEUR 330 million & US$ 67 million
AustraliaUS$ 284 million over 20 yearsAUD 288 million
Spain SpainUS$ 240 million over 20 yearsEUR 190 million
Sweden SwedenUS$ 38 million over 15 yearsSEK 276 million
South AfricaUS$ 20 million over 20 yearsUS$ 20 million
Brazil BrazilUS$ 20 million over 20 yearsUS$ 20 million
TOTALUS$ 8 billion (approximately) 

http://archive.today/2021.05.28-164114/https://iffim.org/donors

Categories
Publications

Social bonds in response to the Covid-19 crisis: when financial markets save lives

Social bonds are an attractive investment for worldwide institutional and individual investors looking for a socially responsible investment with a clear, unambiguous purpose and a portfolio diversification opportunity with attractive risk-adjusted returns. Although the social bond market has been growing fast, it has so far remained a niche sector.

…Over the last few weeks, several social Covid-19 bonds have already been issued by a number of multilateral institutions and public agencies and are already generating significant investor interest, paving the way for more issuances. The stage is now set for social bonds to move from a niche solution to a mainstream one.

http://archive.today/2021.09.06-173555/https://www.ecmi.eu/sites/default/files/when_financial_markets_save_lives_ecmi_commentary.pdf

Categories
News

Pfizer Reaps Hundreds of Millions in Profits From Covid Vaccine – The New York Times

The vaccine brought in $3.5 billion in revenue in the first three months of this year, nearly a quarter of its total revenue, Pfizer reported. The vaccine was, far and away, Pfizer’s biggest source of revenue.

On Tuesday, the company announced just how much money the shot is generating.

The vaccine brought in $3.5 billion in revenue in the first three months of this year, nearly a quarter of its total revenue, Pfizer reported. The vaccine was, far and away, Pfizer’s biggest source of revenue.

The company did not disclose the profits it derived from the vaccine, but it reiterated its previous prediction that its profit margins on the vaccine would be in the high 20 percent range. That would translate into roughly $900 million in pretax vaccine profits in the first quarter.

https://www.nytimes.com/2021/05/04/business/pfizer-covid-vaccine-profits.html

Categories
News

Court approves settlement in Shiley heart-valve case – United Press International

Published 19 August 1992

New York-based Pfizer said the agreement will cost it between $165 million and $215 million, on a pretax basis, and will be offset by proceeds from the sale of most of its Shiley Inc. assets earlier this year as well as expected insurance reimbursements.

https://www.upi.com/Archives/1992/08/19/Court-approves-settlement-in-Shiley-heart-valve-case/4515714196800/

Categories
Videos

Lockdown legacy facing future generations – Dr Rob Verkerk, Pandemic Podcast

Rob Verkerk, Founder, Executive and Scientific Director of the Alliance for Natural Health International, a scientist who has for 30 years been exploring positive ways to span the gulfs between science and the law, between academia and industry, and between governments and their people.

Backup mirror:

Mirrored on odysee.com

Categories
Publications

Justice Department Announces Largest Health Care Fraud Settlement in Its History – US Department of Justice

Published 9 September 2009

WASHINGTON – American pharmaceutical giant Pfizer Inc. and its subsidiary Pharmacia & Upjohn Company Inc. (hereinafter together “Pfizer”) have agreed to pay $2.3 billion, the largest health care fraud settlement in the history of the Department of Justice, to resolve criminal and civil liability arising from the illegal promotion of certain pharmaceutical products, the Justice Department announced today.

https://www.justice.gov/opa/pr/justice-department-announces-largest-health-care-fraud-settlement-its-history

Categories
News

Anger at deadly Nigerian drug trials – BBC

Published 20 June 2007

Pfizer tested the then unregistered drug in Nigeria’s north-western Kano State during an outbreak of meningitis which had affected thousands of children.

Officials in Kano say more than 50 children died in the experiment, while many others developed mental and physical deformities.

…After more than a decade of silence, the Nigerian government has decided to sue Pfizer, seeking $7bn (£3.5bn) in damages for the families of children who allegedly died or suffered side-effects in the experiment.

http://news.bbc.co.uk/1/hi/world/africa/6768799.stm

Categories
News

Meet The 40 New Billionaires Who Got Rich Fighting Covid-19 – Forbes

Shortly after the World Health Organization declared Covid-19 a global pandemic on March 11, 2020, markets collapsed and economies around the world plunged into recession. At the same time, hundreds of billionaires fell from the ranks of Forbes’ World’s Billionaires list, capturing a snapshot of the pandemic’s impact on the fortunes of the world’s wealthiest people.

https://www.forbes.com/sites/giacomotognini/2021/04/06/meet-the-40-new-billionaires-who-got-rich-fighting-covid-19/

Categories
Publications

List of largest pharmaceutical settlements – Wikipedia

Wikipedia snapshot from 9 March 2021:

YearCompanySettlementViolation(s)Product(s)Laws allegedly violated
(if applicable)
2012GlaxoSmithKline[1][6]$3 billion ($1B criminal, $2B civil)Criminal: Off-label promotion, failure to disclose safety data.
Civil: paying kickbacks to physicians, making false and misleading statements concerning the safety of Avandia, reporting false best prices and underpaying rebates owed under the Medicaid Drug Rebate Program
Avandia (not providing safety data), Wellbutrin, Paxil (promotion of paediatric use), Advair, Lamictal, Zofran, Imitrex, Lotronex, Flovent, ValtrexFalse Claims Act, FDCA
2009Pfizer[2]$2.3 billionOff-label promotion, kickbacksBextra, Geodon, Zyvox, LyricaFalse Claims Act, FDCA
2013Johnson & Johnson[7]$2.2 billionOff-label promotion, kickbacksRisperdal, Invega, NesiritideFalse Claims Act, FDCA
2012Abbott Laboratories[8]$1.5 billionOff-label promotionDepakoteFalse Claims Act, FDCA
2009Eli Lilly[9]$1.4 billionOff-label promotionZyprexaFalse Claims Act, FDCA
2001TAP Pharmaceutical Products[10]$875 millionMedicare fraud, kickbacksLupronFalse Claims Act, Prescription Drug Marketing Act
2012Amgen[11]$762 millionOff-label promotion, kickbacksAranespFalse Claims Act, FDCA
2010GlaxoSmithKline[12]$750 millionPoor manufacturing practicesKytril, Bactroban, Paxil CR, AvandametFalse Claims Act, FDCA
2005Serono[13]$704 millionOff-label promotion, kickbacks, monopolistic practicesSerostimFalse Claims Act
2008Merck[14]$650 millionMedicare fraud, kickbacksZocor, Vioxx, PepsidFalse Claims Act, Medicaid Rebate Statute
2007Purdue Pharma[15]$601 millionOff-label promotionOxycontinFalse Claims Act
2010Allergan[16]$600 millionOff-label promotionBotoxFalse Claims Act, FDCA
2010AstraZeneca[17]$520 millionOff-label promotion, kickbacksSeroquelFalse Claims Act
2007Bristol-Myers Squibb[18]$515 millionOff-label promotion, kickbacks, Medicare fraudAbilify, SerzoneFalse Claims Act, FDCA
2002Schering-Plough[19]$500 millionPoor manufacturing practicesClaritinFDA Current Good Manufacturing Practices
2006Mylan[20]$465 millionMisclassification under the Medicaid Drug Rebate ProgramEpiPen (epinephrine)False Claims Act
2006Schering-Plough[21]$435 millionOff-label promotion, kickbacks, Medicare fraudTemodar, Intron A, K-Dur, Claritin RediTabsFalse Claims Act, FDCA
2004[22]Pfizer$430 millionOff-label promotionNeurontinFalse Claims Act, FDCA
2008Cephalon[23]$425 millionOff-label promotion[23]Actiq, Gabitril, ProvigilFalse Claims Act, FDCA
2010Novartis[24]$423 millionOff-label promotion, kickbacksTrileptalFalse Claims Act, FDCA
2003AstraZeneca[25]$355 millionMedicare fraudZoladexPrescription Drug Marketing Act
2004Schering-Plough[26]$345 millionMedicare fraud, kickbacksClaritinFalse Claims Act, Anti-Kickback Statute

http://archive.today/2021.05.05-122141/https://en.wikipedia.org/wiki/List_of_largest_pharmaceutical_settlements

Categories
News

Inside the Pfizer/BioNTech COVID-19 vaccine trial: ‘We knew the world was watching and waiting for results’ – BioPharma Reporter

A request for Emergency Use Authorization in the US was submitted the same month; and the vaccine was then authorized in the US on December 11 (shortly after UK authorization on December 2).

The trial is not over, however: as all subjects are monitored for a further two year period. And the next step is to test the vaccine in groups that cannot currently receive the vaccine due to a lack of data – such as pregnant women and children (Pfizer has already started a trial in pregnant women​ and one in children is set to follow later this year).

https://www.biopharma-reporter.com/Article/2021/03/03/Inside-the-Pfizer-BioNTech-COVID-19-vaccine-trial-Insights-on-speed-agility-and-digital-development

Categories
News

let’s take a look Pfizer’s history of ‘ethical standards’ – Architects for Social Housing

Last September, Pfizer’s CEO, Albert Bourla, assured the public that ‘we will develop our product, develop our vaccine, using the highest ethical standards’. And the NHS has assured us of the same rigorous standards. So let’s take a look Pfizer’s history of ‘ethical standards’.

In 1992, Pfizer agreed to pay between $165 million and $215 million to settle lawsuits arising from the fracturing of the Bjork-Shiley Convexo-Concave heart valve, which by 2012 had resulted in 663 deaths.

Court approves settlement in Shiley heart-valve case Pfizer Inc. said Wednesday a federal judge has approved the previously announced agreement for settlement of claims to patients with the Bjork-Shiley… upi.com

In 1996, Pfizer conducted an unapproved clinical trial on 200 Nigerian children with its experimental anti-meningitis drug, Trovafloxacin, without parental consent, which led to the death of 11 children from kidney failure and left dozens more disabled. http://news.bbc.co.uk/1/hi/world/africa/6768799.stm …

In 2011, Pfizer paid just $700,000 to four families who had lost a child, and set up a $35 million fund for those disabled by their drug experiment. This cover-up was the basis to the John Le Carré book and film, The Constant Gardener.

Pfizer: Nigeria drug trial victims get compensation US-based pharmaceutical giant Pfizer makes the first compensation payment to Nigerian families affected by a controversial drug trial 15 year… bbc.co.uk

In 2004, Pfizer’s subsidiary, Warner-Lambert, was fined $430 million to resolve criminal charges and civil liabilities for the fraudulent promotion of its epilepsy drug, Neurontin, paying and bribing doctors to prescribe it for uses not approved by the FDA.https://www.justice.gov/archive/opa/pr/2004/May/04_civ_322.htm …

In 2009, Pfizer spent $25.8 million lobbying Congressional lawmakers and federal agencies like the Department of Health and Human Services. Image of government building columns Pfizer Inc Lobbying Profile Pfizer Inc spent $25,819,268 lobbying in 2009. See the details. opensecrets.org

Pfizer’s expenditure on federal lobbying between 2006 and 2014 came to $89.89 million. In 2019 the second largest pharmaceutical company in the world spent $11 million lobbying the US federal government. Image of government building columns Pfizer Inc Lobbying Profile Pfizer Inc spent $11,000,000 lobbying in 2019. See the details. opensecrets.org

In 2009, Pfizer paid the largest health care fraud settlement and criminal fine ever, paying $2.3 billion to avoid criminal and civil liability for fraudulently marketing its anti-inflammatory drug, Bextra, which the FDA had refused due to safety concerns.

Justice Department Announces Largest Health Care Fraud Settlement in American pharmaceutical giant Pfizer Inc. and its subsidiary Pharmacia & Upjohn Company Inc. (hereinafter together “Pfizer”) have agreed to pay $… justice.gov

In 2009, Pfizer paid $750 million to settle 35,000 claims that its diabetes drug, Rezulin, was responsible for 63 deaths and dozens of liver failures. In 1999, an epidemiologist at the FDA said Rezulin was ‘one of the most dangerous drugs on the market’. LA Times logo

Pfizer Agrees to Settle Suit Over Diabetes Drug Rezulin Pfizer Inc. agreed Friday to settle a lawsuit over the diabetes drug Rezulin after a jury earlier in the day awarded $43 million to a Texas woman wh… latimes.com

In 2010, Pfizer was ordered to pay $142.1 million in damages for violating a federal anti-racketeering law by its fraudulent sale and marketing of its epilepsy drug Neurontin for uses not approved by the FDA, including for migraines and bi-polar disorder.

Neurontin Lawsuits – Pfizer Illegal Marketing, Injury Claims Pfizer Marketing Illegal Neurontin. Pfizer Inc. has been ordered to pay $142.1M in damages for violating a federal antiracketeering law in its marketing. yourlawyer.com

In 2010, Pfizer admitted that, in the last 6 months of 2009 alone, it had paid $20 million to 4,500 doctors in the US for consulting and speaking on its behalf, and $15.3 million to 250 academic medical centres for clinical trials.

Pfizer admits paying $35 million to doctors over last 6 months Pfizer among other large pharmaceutical companies recently disclosed payments to doctors and other medical professionals for consulting and … news-medical.net

In 2012, Pfizer paid $45 million to settle charges of bribing doctors and other health-care professionals employed by foreign governments in order to win business. https://www.sec.gov/news/press-release/2012-2012-152htm …

The Chief of the Foreign Corrupt Practices Act Unit said: ‘Pfizer subsidiaries in several countries had bribery so entwined in their sales culture that they offered points and bonus programs to improperly reward foreign officials who proved to be their best customers’.

By 2012, Pfizer had paid $1.226 billion to settle claims by nearly 10,000 women that its hormone replacement therapy drug, Prempro, caused breast cancer.

In 2013, Pfizer agreed to pay $55 million to settle criminal charges of failing to warn patients and doctors about the risks of kidney disease, kidney injury, kidney failure and acute interstitial nephritis caused by its proton pump inhibitor, Protonix.

In 2013, Pfizer set aside $288 million to settle 2,700 claims that its stop-smoking drug, Chantix, caused suicidal thoughts and psychological disorders. The FDA subsequently determined that Chantix is probably associated with a higher risk of heart attack.

In 2013, Pfizer absolved itself of claims that its antidepressant, Effexor, caused congenital heart defects in the children of pregnant woman by arguing that the prescribing obstetrician was responsible for advising the patient about the medication’s use. https://europepmc.org/article/PMC/6424813 …

In 2014, Pfizer paid a further $325 million to settle a lawsuit brought by health-care benefit providers who claimed the company marketed its epilepsy drug, Neurontin, for purposes unapproved by the FDA.

In 2014, Pfizer paid $35 million to settle a law suit accusing its subsidiary of promoting the kidney transplant drug, Rapamune, for unapproved uses, including bribing doctors to prescribe it to patients.

In 2016, Pfizer was fined a record £84.2m for overcharging the NHS for its deregulated anti-epilepsy drug, Phenytoin, by 2,600% (from £2.83 to £67.50 a capsule), increasing the cost to UK taxpayers from £2 million in 2012 to about £50 million in 2013.

In May 2018, Pfizer had 6,000 lawsuits pending against claims that its testosterone replacement therapy products cause strokes, heart attacks, pulmonary embolism and deep vein thrombosis, and were marketed at healthy men for uses not approved by the FDA.

https://archive.is/jOIia